• Therapeutic Category : iron deficiency anemia (IDA) 
  • API : Chemical Synthetic
  • Injectable Strength : Injection: 50 mg/mL
    -    100 mg iron/2 mL single-dose vial
    -    750 mg iron/15 mL single-dose vial 
    -    1,000 mg iron/20 mL single-dose vial
  • Formosa Laboratories’ Development Status :
    API: Complete
    Injecatble: Complete 
  • Available Regulatory Filing :
    EUDMF
    Taiwan DMF 
    USDMF
  • Innovator Brand (USA) : INJECTAFER

Mechanism of Action :

Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose,
a carbohydrate polymer that releases iron.

Indication :

Injectafer is indicated for the treatment of: 

  • iron deficiency anemia (IDA) in:
    - adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron.
    - adult patients who have non-dialysis dependent chronic kidney disease. 
  • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity.

‌You may be interested in

Gadoterate Meglumine Injectable

Eribulin Mesylate Injectable

Difelikefalin Injectable

Disclaimer
 

Please be reminded that some products listed above are still patented and can only be made available for R & D use as permitted under Article 69, Paragraph 1 of the Patent Act of Japan; Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004; or Article 69 (5) of the Patent Law of People’s Republic of China; or Article 60 of the Patent Act of Republic of China. We will not make, sell, offer for commercial sale or export the products listed above in/into regions or countries in which substance patents are still existing and we will not be responsible if the use of any of the above products infringes on any patent in your country.

‌

持続可能性

会社概要

閉じる